Sangamo Therapeutics (SGMO) Misses Q1 EPS by 2c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
UPDATE: RBC Capital Starts Sangamo BioSciences (SGMO) at Outperform
May 3, 2021 4:12 PM EDT(Updated - May 3, 2021 4:15 PM EDT)
RBC Capital analyst Luca Issi initiates coverage on Sangamo BioSciences (NASDAQ: SGMO) with a Outperform rating and a price target of $22.00 (from $26.00).
The analyst comments "SGMO has trail blazed the field of gene-editing using zinc... More
